

HENDLISZ Alain, MD, PhD**Gastroenterology-Digestive Oncology**

Avenue Penelope 22/1, Brussels 1190

alain.hendlisz@gmail.com - Phone: +32 475742599website ideagaston.eu/linkedin <https://www.linkedin.com/in/alain-hendlisz-180b2a4/>**CLINICAL PROFESSIONAL EXPERIENCE**

2021-2024	Head of Digestive Oncology Research , Hôpital Universitaire de Bruxelles (HUB) Associate Head, Digestive Oncology Department , Hôpital Universitaire de Bruxelles (HUB)
2002-2021	Head of Gastroenterology, Digestive Oncology Clinic , Internal Medicine Department (<i>Head Prof Piccart/Prof Ahmad Awada</i>) Institut Jules Bordet (IJB) Head of Endoscopy Department , Institut Jules Bordet
2002-2020	Board Member , Institut Jules Bordet Medical Committee Board
2000-2002	Associate Head, Gastroenterology Clinic (<i>Head Prof Harry Bleiberg</i>), Internal Medicine Department–Institut Jules Bordet (<i>Head Prof Martine Piccart</i>)
1993-2003	Consultant Hepatologist and Gastroenterology , Gastroenterology Department, HIS (Hôpitaux Iris Sud) CHU Etterbeek-Ixelles – Brussels - (<i>Head, Dr B. Des Marez</i>) & CHU Molière (<i>Head Dr S. Jamsin</i>)
1993-2000	Resident, Gastroenterology Clinic (<i>Head Prof Harry Bleiberg</i>), Internal Medicine Department (<i>Head Prof Jean Klastersky</i>)–Institut Jules Bordet

EDUCATION & ACADEMIC PROFILE

2021 -	Chargé de cours Université Libre de Bruxelles (ULB), Medicine Faculty
2016-2021	Maître de Conférences Université Libre de Bruxelles (ULB), Medicine Faculty
2015	PhD thesis “Multimodality imaging for treatment response prediction in colorectal cancer”, Université Libre de Bruxelles
2014	Board certification Digestive Oncology
2002-	Assistant Professor Internal Medicine ASHU (Prof Klastersky (IJB), Prof A-P Meerts, (HUB))
2002-	Deputy academic supervisor in Clinical Pharmacy
1993	Board Certification Hepato-Gastroenterology
1991-1993	Post-Graduate Specialty Training Gastroenterology (Prof Michel Cremer) 1992-1993 Centre Hospitalier Universitaire Tivoli, La Louvière, Belgium-Dr J.Morobe 1991-1992 Hôpital Universitaire Erasme-Brussels, Belgium-Prof. M.Cremer
1988-1991	Post-graduate Specialty Training Internal Medicine 1989-1991 Centre Hospitalier Molière-Longchamp, Brussels-Dr. Fr. Lustman 1988-1989 Institut Jules Bordet-Brussels, Belgium-Prof. J. Klastersky
1988	Master Medicine Université Libre de Bruxelles (ULB) Magna cum laude
1984	Bachelor Medicine Université Libre de Bruxelles (ULB) Magna cum laude
1975 – 1981	High School : Latin-Math Section - Athénée Robert Catteau, Brussels

SCIENTIFIC SOCIETIES Activities

2015-	ONCODISTINCT network
2008-	Scientific Oncological Board-Foundation Roi Baudouin
2003 -	Belgian Group of Digestive oncology (BGDO) – Founding & Board member
	2022- Chairman
	2019-2022 Vice-Chairman (Chairman Prof Marc Peeters)
2003-	Editor, Digestive Oncology Section, Current Opinion in Oncology
2003 -	European Society for Medical Oncology (ESMO)
2003 -	American Society for Clinical Oncology (ASCO)
2002 -	European Organization for Research and Treatment of Cancer (EORTC)G
2002 -	Fédération Francophone de Cancérologie Digestive (FFCD)
1988 -	Société Royale Belge de Gastro-entérologie (SRBGE)

AREAS OF EXPERTISE/ RESEARCH PROJECTS

Clinical:

- Digestive Oncology
- Hepato-Gastroenterology
- Diagnostic and Therapeutic Endoscopy

Team Leadership:

- Oversight of Physician, Nurse, Clinical Research, and Translational Research Teams
- Collaboration with Translational Laboratories

Research:

- Principal Investigator in over 50 company-sponsored trials spanning phases I, II, III, and IV studies
- Co-investigator in over 150 company- and investigator-sponsored trials
- Creator and Principal Investigator of 19 investigator-sponsored trials

Research Focus Areas: GI oncology, including Colorectal and Anal Margin Cancer, Hepatocellular Carcinoma, Upper Gastrointestinal Cancers, Biliary Duct Carcinomas, and Neuroendocrine Tumours.

- Early Drug Development
- New Treatment Modalities such as Radioembolisation, Locoregional Treatments, Peptid Radionuclide Therapy (PRRT), ...
- Biomarkers for Prognostic and Response Assessment, including
 - Liquid Biopsies
 - Metabolic Imaging
 - Body Mass Composition
- Oligometastatic and Oligorefractory Diseases
- Adjuvant and Neoadjuvant approaches
- Deciphering mechanisms of resistance to therapies

Research Philosophy: PRIMUM NON NOCERE: finding the right approach for the right patient

Development of Patient-Centered Investigator-Sponsored Studies (ISS) aiming at:

- *Enhancing Treatment Tolerance* (e.g., **Doge** EudraCT 2008-000551-10, **Momentum** ClinicalTrials.gov NCT01843725)
- *Identifying Phenotypically Aggressive Diseases* (e.g., **Coriolan** ClinicalTrials.gov NCT01591590, **Regard-C** EudraCT number: 2012-005655-16, Imaging Score)
- *Exploring New Therapeutic Approaches in Challenging Clinical Scenarios* (e.g., **Radioembolisation** in Refractory Liver-Metastatic Colorectal Cancer, **Tryphon** ClinicalTrials.gov NCT01686880, **Mime-A** study ClinicalTrials.gov NCT03339843, **Artemis-Eso** ClinicalTrials.gov NCT03307941)

- *Defining Patient Populations Likely to Benefit from Treatment* (e.g., **Serial FDG-PET** in Metastatic Colorectal Cancer, **SoMore** ClinicalTrials.gov NCT01290926, **Pepita** Eudract 2009-011445-13)
- *Establishing Longitudinal Liquid Biopsy-based Tumor Banks* (e.g., **Chronos & Kairos** B079201526624)

GCP AND RESEARCH AUDITS

GCP training: Last Certification in February 2022

AFMPS Audit jan 2015 (DoGE01 trial)

AFMPS Audit may 2013 (BAY73-4506/14387 trial)

FDA Audit may 2006 (Panitumumab phase III trial)

AWARDS

- 1995: Award Fernand Hirsh AMUB 1994 for the presentation of: "Une complication rare du traitement endoscopique d'une pancréatite chronique calcifiante" at the S.I.H.G.E.
- 2009: Award from the Kanker Plan Cancer for the project: "Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer: PePiTA trial (PNC_29_059)".
- 2011: Award from *Les Amis de l'Institut Bordet asbl* for the project: "Correlation of metabolic progression Index and patient's Outcome assessment in advanced Colorectal cancer disease (CORIOLAN study)".
- 2011: Award from *Fonds Henri & Jeanne Oehm (Fondation Roi Boudouin) 2011* for the project: "Correlation of metabolic progression Index and patient's Outcome assessment in advancedColorectal cancer disease (CORIOLAN study)".
- 2016: KBF Award Ceremony of the Funds for medical scientific research gérés par la Fondation Roi Baudouin for the project : *ARTEMIS Study: Assessment of Metabolic Response To a single course of chemotherapy (CT) as surrogate for pathological Complete Response (pCR) after radiochemotherapy (RTCT)in locally advanced Esophageal and gastro-esophageal junction cancer.*
- 2019: Award Dauphin d'Argent for the « Chronos & Kairos »movie (10th edition Cannes CorporateMedia & TV Awards 2019)

REVIEW COMMITTEES

Expert member	INCa revision and evaluation committees 2022, 2023 Independent Data Monitoring Committees (IDMC), Scientific Board Fondation Roi Baudouin (KBF)
---------------	---

Alain HENDLISZ: Curriculum Vitae Annexes

PUBLICATIONS (First or Senior Author)

	Publications number (total)	Publications number (1st or last author)
International Peer-reviewed	169	51
National Peer-reviewed	15	6
Abstracts in national/international congresses	70	21
Citations Number	12317	
H-index	43	
i10-index	125	

International peer-reviewed:

- Englert Y, Delvigne A, Vekemans M, Lejeune B, **Hendlisz A**, De Maertelaer G, Leroy F. Is fresh or frozen semen to be used in in-vitro fertilization with donor sperm? *Fertil-Steril*, 1989 Apr; 51 (4): 661-4.
- Hendlisz A**, Rijpens F, Gay F, Vangossum A, Cremer M. Spinal epidural abscess after endoscopic treatment for chronic pancreatitis. *Pancreas*, 1995 Mar; 10-2: 204-6.
- Hendlisz A**, Bleiberg H. Diagnosis and treatment of gastric cancer. *Drugs*, 1995 May; 49 (5): 711-20.
- Bleiberg H, Jeziorski K, **Hendlisz A**, Gerard B. Place de la radiothérapie dans les cancers de l'estomac. *Bull Cancer* 1997 Sept; 84: 913-916.
- Gerard B, Bleiberg H, Van Daele D, Gil Th, **Hendlisz A**, Di Leo A, Fernez B, Brienza S. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. *Anti-CancerDrugs* 1998 Apr; 9:301-305.
- Caroli-Bosc FX, Van Laethem JL, Michel P, Gay F, **Hendlisz A**, Forget F, Bleiberg H. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) + leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. *Eur Jour Cancer* 2001 Oct; 37:1828-32.
- Bleiberg H, **Hendlisz A**. Advanced colorectal cancer treatment in Europe: what have we achieved? *Anti-cancer Drugs*. 2002 Jun; 13(5):461-71.
- Legendre H, Decaestecker C, Nagy N, **Hendlisz A**, Schüring MP, Salmon I, Gabius HJ, Pector JC, Kiss R. Prognostic Values of Galectin-3 and the Macrophage Migration Inhibitory Factor (MIF) in Human Colorectal Cancers. *Mod Pathol*. 2003 May; 16(5):491-504.
- Delaunoy T, Maréchal R, **Hendlisz A**, Eisendrath P, Legendre H, Pector JC, DeBecker D, Bleiberg H. Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. *Anti-cancer Drugs* 2004 Aug; 15(7):725-8.
- Legendre H, Decaestecker C, Goris Gbenou M, Nagy N, **Hendlisz A**, André S, Pector JC, Kiss R, Gabius HJ. Prognostic stratification of Dukes B colon cancer by a neoglycoprotein. *Int J Oncol*. 2004 Aug; 25(2):269-76.
- Awada A, Mano M, **Hendlisz A**, Piccart M. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. *Expert Rev Anticancer Ther*. 2004 Feb; 4(1):53-60.
- Awada A, **Hendlisz A**, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. *Br J Cancer*. 2005 May 23; 92(10):1855-61.
- Personeni N, **Hendlisz A**, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. *Semin Oncol* 2005 Dec; 32(6 Suppl 9):S59-62.
- Hendlisz A**. Molecular medicine: are we, clinicians, becoming old-fashioned? *Curr Opin Oncol*. 2005 Jul;

- 17(4):376.
15. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, [Hendlisz A](#), Van Laethem JL. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. *Br Journal of Cancer* 2006 Feb 27; 94(4):481-5.
16. Baize N, Gerard B, Bleiberg H, Caroli-Bosc FX, Berthier F, Legendre H, Pector JC, [Hendlisz A](#). Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. *Gastroenterol Clin Biol* 2006 Dec; 30:(12) 1349-53.
17. Bleiberg H, Autier P, Huet F, Schrauwen AM, Staquet E, Delaunoit T, [Hendlisz A](#), Wyns C, Panzer JM, Caucheteur B, Eisendrath P, Grivegnée A. Colorectal cancer (CRC) screening using sigmoidoscopy followed by colonoscopy: a feasibility and efficacy study on a cancer institute-based population. *Ann Oncol* 2006 Aug;17(8):1328-32.
18. Vereecken P, Awada A, Ghanem G, Marques da Costa C, Larsimont D, Simoens C, Mendes da Costa P, [Hendlisz A](#). A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery. *Med Sci Monit.* 2007 Jun; 13(6):CS75-7.
19. Van Cutsem E, Peeters M, Siena S, Humblet Y, [Hendlisz A](#), Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol.* 2007 May 1; 25(13):1658-64.
20. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, [Hendlisz A](#), Hirte HW, Eder JP, Lenz HJ, Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. *Oncologist.* 2007 Apr; 12(4):426-37.
21. Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, [Hendlisz A](#), Van Laethem JL. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. *Oncology.* 2007; 73(1-2):41-51.
22. [Hendlisz A](#). Don't believe... check! *Curr Opin Oncol.* 2007; 19(4); 383.
23. Liberale G, Van den Eynde M, [Hendlisz A](#), El Nakadi I. Recommendations for general surgeons facing incidental peritoneal carcinomatosis of colorectal origin. *Eur J Surg Oncol.* 2008 Jul; 34(7):725-6.
24. Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, [Hendlisz A](#), Van Laethem JL. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. *Pancreas.* 2008 Apr; 36(3):e16-21.
25. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van den Eynde M, [Hendlisz A](#). Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. *Phys Med Biol* 2008 Nov; 5322: 6591-603.
26. Van den Eynde M, Flamen P, El Nakadi I, Liberale G, Delatte P, Larsimont D, [Hendlisz A](#). Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90microspheres. *Clin Nucl Med* 2008 Oct; 33(10):697-9.
27. Vos B, Awada A, [Hendlisz A](#). Small-cell carcinoma of the pancreas: an extensive review of the literature with emphasis on therapy and prognosis. Review article. *Cancer Therapy* 2008;6:857-64.
28. Peeters M, Siena S, Van Cutsem E, Sobrero A, [Hendlisz A](#), Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. *Cancer.* 2009 Apr 1;115(7):1544-54.
29. Laurent S, Monsaert E, Boterberg T, Demols A, Borbath I, Polus M, [Hendlisz A](#), de Hemptinne B, Mahin C, Scalliet P, Van Laethem JL, Peeters M. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. *Ann Oncol.* 2009 Aug; 20(8):1369-74.
30. [Hendlisz A](#), Golfopoulos V. Adjuvant trials design in colon cancer. *Curr Opin Oncol.* 2009 Jul; 21(4):367-8.

31. Van den Eynde M, Awada A, [Hendlisz A](#). Is tailored adjuvant treatment for colon cancer possible? *Clin Colorectal Cancer*. 2010 Jan; 9(1):15-21.
32. Deleporte A, Flamen P, [Hendlisz A](#). State of the art: radiolabeled microspheres treatment for liver malignancies. *Expert Opin Pharmacother*. 2010 Mar; 11(4):579-86.
33. [Hendlisz A](#), Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P. Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. *J Clin Oncol*. 2010 Jun 21:3687-94.
34. Golfinopoulos V, [Hendlisz A](#). The unfulfilled promise of molecular diagnosis in colorectal cancer. *Curr Opin Oncol*. 2010 Jul; 22(4):362-3.
35. Nevens F, Van Vlierberghe H, D'Heygere F, Delwaide J, Adler M, Henrion J, Lenaert A, [Hendlisz A](#), Michielsens P, Bastens B, Brenard R, Laureys A and the BERNAR-1 Study Group. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. *Acta Gastro-enterologica Belgica* 2010 April; 73,2:223-8.
36. Vos B, Rozema T, Miller RC, [Hendlisz A](#), Van Laethem JL, Khanfir K, Weber DC, El Nakadi I, Van Houtte P. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study. *Dis Esophagus*. 2011 May; 24(4):258-64.
37. Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, [Hendlisz A](#). Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial. *J Clin Pharmacol*. 2011 Dec; 51(12):1674-84.
38. Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, [Hendlisz A](#), Flamen P, Buvat I. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging. *J Nucl Med*. 2011 Mar; 52(3):354-61.
39. Buyse M, Quinaux E, [Hendlisz A](#), Golfinopoulos V, Tournigand C, Mick R. Progression-free survival ratio as end point for phase II trials in advanced solid tumors. *J Clin Oncol*. 2011 May 20; 29(15):e451-2; author reply e453.
40. Mouton C, Ronson A, Razavi D, Delhay F, Kupper N, Paesmans M, Moreau M, Nogaret JM, [Hendlisz A](#), Gidron Y. The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer. *Auton Neurosci*. 2012 Jan 26;166(1-2):96-9.
41. Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Maréchal R, [Hendlisz A](#), Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. *Ann Oncol*. 2012 Mar;23(3):570-6.
42. Awada A, [Hendlisz A](#), Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. *Eur J Cancer*. 2012 Mar;48(4):465-74. Epub 2012 Jan 27
43. [Hendlisz A](#), Deleporte A. The confusion around neuroendocrine tumors. *Curr Opin Oncol*. 2012 Jul;24(4):431-2.
44. [Hendlisz A](#), Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P. *Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy*. *Ann Oncol* 2012 Jul;23(7):1687-93.
45. Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, [Hendlisz A](#), Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

Intrapatent cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. *J Clin Oncol*. 2012 Aug 10;30(23):2861-8.

46. Buvat I, Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, [Hendlisz A](#), Flamen P. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. *Eur J Nucl Med Mol Imaging* 2012 Oct;39(10):1628-34.
47. [Hendlisz A](#), Golfinopoulos V, Deleporte A, Paesmans M, Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbier G, Fried M, Awada A, Piccart M, Laethem JL, Flamen P. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. *BMC Cancer*. 2013 Apr 12;13(1):190.
48. Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, [Hendlisz A](#). Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. *Invest New Drugs*. 2013 Jan 24.
49. Maisonneuve J-A, Garcia C.A., Necib H, Vanderlinden B, [Hendlisz A](#), Flamen P, Buvat I. Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy. *Eur J Nucl Med Mol Imaging*, 2013 Jan;40(2):166-74.
50. Awada AH, Dumez H, [Hendlisz A](#), Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. *Invest New Drugs*. 2012 Nov 17.
51. [Hendlisz A](#), Charette N, Awada A, Deleporte A. Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints. *Curr Opin Oncol*. 2013 Jul;25(4):407-8
52. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; [CORRECT Study Group](#). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2013 Jan 26;381(9863):303-12.
53. Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, [Hendlisz A](#), Decosta L, Vogl FD, Passalacqua R. Chemotherapy treatment patterns and neutropenia management in gastric cancer. *Gastric Cancer*. 2014 May 5.
54. Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, [Hendlisz A](#). Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study. *BMC Cancer*. 2014 May 30;14(1):3857
55. [Hendlisz A](#), Deleporte A, Vandeputte C. In times of crisis, go liquid! *Curr Opin Oncol*. 2014 Jul;26(4):440.
56. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; [PETACC-8 Study Investigators](#). Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Eur J Cancer*. 2014; S0959-8049(14)00811-9
57. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, [Hendlisz A](#), Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Belleria C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). *Eur J Cancer*. 2014 Sep 22. S0959-8049(14)00811-9.

58. Veereman G, Robays J, Verleye L, Leroy R, Rolfo C, Van Cutsem E, Bielen D, Ceelen W, Danse E6, De Man M, Demetter P, Flamen P, [Hendlisz A](#), Sinapi I, Vanbeckevoort D, Ysebaert D, Peeters M. Pooled analysis of the surgical treatment for colorectal cancer liver metastases. *Crit Rev Oncol Hematol*. 2015 Jan 14
59. Vouche M, Salem R, Miller FH, Lemort M, Vanderlinden B, De Becker D, [Hendlisz A](#), Flamen P. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. *P5Clin Imaging*. 2015 Jan 8. pii: S0899-7071(14)
60. [Hendlisz A](#), Deleporte A, Vandeputte C, Charette N, Paesmans M, Guiot T, Garcia C, Flamen P. Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol. *BMJ Open*. 2015 Mar 9;5(3).
61. Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, D'Hoore A, Iserentant H, [Hendlisz A](#), Mazzone M. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. *Gut*. 2015;26 2014-
62. [Hendlisz A](#). Of art and science: is personalized medicine getting personal enough? *Curr Opin Oncol*. 2015 Jul;27(4):349-50.
63. Bouazza F, Poncelet A, Garcia C, Delatte Ph, Engelhom JL, Gomez Galdon M, Deleporte A, [Hendlisz A](#), Vanderlinden B, Flamen P, Donckier V. Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma. *World J Gastroenterol* 2015 August 28; 21(32): 9666-9670
64. Venugopal B, Aamdal S, Evans J, Rasch W, Dueland S, [Hendlisz A](#), Hernes K, Hagen S, Awada A. A first in human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2015 Aug 20.
65. Van Daele D, Puleo F, Dumont R, Polus M, Loly C, Martinive P, Meunier P, Collignon J, [Hendlisz A](#), Maréchal R, Louis E, Van Laethem JL. Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma. *Rev Med Suisse*. 2015 Aug 26;11(483):1543-8.
66. [Hendlisz A](#), Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart M, Flamen P. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. *PLoS One*. 2015 Sep 30;10(9):e0138341
67. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; [RAISE Study Investigators](#). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*. 2015 May;16(5):499-508.
68. Elez E, [Hendlisz A](#), Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. *Br J Cancer*. 2016 Feb 16;114(4):372-80
69. Van Den Heuvel B, Peeters M, [Hendlisz A](#), Van den Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, Van Laethem JL, Lybaert W, Holbrechts S, Rolfo C. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. *Minerva Chir*. 2016 Jan 15
70. [Hendlisz A](#), Bleiberg H. Too little benefit for too much toxicity: rethinking the adjuvant development model in colon cancer. *Curr Opin Oncol*. 2016 Jul;28(4):345-7.
71. Lucidi V, [Hendlisz A](#), Van Laethem JL, Donckier V. Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases. *World J Gastroenterol*. 2016 Apr 21;22(15):3937-44.
72. Woff E, [Hendlisz A](#), Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. *Eur J Nucl Med Mol Imaging*.

2016 Sep;43(10):1792-801.

73. Farinella E, Safar A, Nasser HA, Bouazza F, Liberale G, Paesmans M, Marechal R, Van Laethem JL, **Hendlisz A**, VanHoutte P, El Nakadi I. Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer. *J Surg Oncol*. 2016 Dec;114(7):833-837.
74. **Hendlisz A**, Puleo F, Deleporte A, Shaza L, Charette N. In Deciphering the future of adjuvant treatment in colon cancer, the journey matters more than the achievements. *Curr Colorectal Cancer Rep* 2016;12:57-66
75. Liberale G, Lecocq C, Garcia C, Muylle K, Covas A, Deleporte A, **Hendlisz A**, Bouazza F, El Nakadi I, Flamen P. Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response. *Anticancer Res*. 2017 Feb;37(2):929-934.
76. Speybrouck S, Claeys L, **Hendlisz A**, Meert AP. Dyspnea and cardia cancer, an unusual etiology. *Rev Med Brux*. 2017;38(3):162-168.
77. **Hendlisz A**. The meaningness of colon cancer sidedness. *Curr Opin Oncol*. 2017 Jul;29(4):286-287
78. Anciaux M, Vandeputte C, **Hendlisz A**. Tackling immunomonitoring in gastrointestinal cancer. *Curr Opin Oncol*. 2017 Jul;29(4):296-305
79. Veereman G, Vlayen J, Robays J, Fairon N, Stordeur S, Rolfo C, Bielen D, Bols A, Demetter P, D'hoore A, Haustermans K, **Hendlisz A**, Lemmers A, Leonard D, Penninckx F, Van Cutsem E, Peeters M Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard? *Crit Rev Oncol Hematol*. 2017 Jun;114:43-52
80. Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); **Belgian Group of Digestive Oncology (BGDO)**; Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. *Eur J Cancer*. 2017 Sep;82:16-24.
81. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreass J, Virdee PS, Dutton P, Love S, GebSKI V, Gray A; **FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators**, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol*. 2017 Sep;18(9):1159-1171.
82. Loney C, Verma B, **Hendlisz A**, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. *BMJ Open*. 2017 Nov 12;7(11)
83. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, **Hendlisz A**, Neyns B, Svrcek M, Moss RA, Ledezine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol*. 2018 Jan 20:
84. Vouche M, De Grez T, Bouazza F, Delatte P, Galdon MG, **Hendlisz A**, Flamen P, Donckier V. Sequential

- tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. *World J Hepatol.* 2017 Dec 28;9(36):1372-1377.
85. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, GebSKI V, Van Buskirk M, Zhao H, van Hazel G; **SIRFLOX and FOXFIRE Global Trial Investigators**. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. *Clin Colorectal Cancer.* 2018 Dec;17(4):e617-e629.
 86. Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, **Hendlisz A**, Vanderlinden B, Flamen P. 90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. *EJNMMI Res.* 2018 Jul 13;8(1):60
 87. Bohlok A, **Hendlisz A**, Bouazza F, Galdon MG, Van de Stadt J, Moretti L, El Nakadi I, Liberale G. The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade. *Int J Colorectal Dis.* 2018 Oct;33(10):1383-1391.
 88. Woff E, **Hendlisz A**, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P. Metabolic Active Tumor Volume and Total Lesion Glycolysis by 18F-FDG PET/CT Validated as Prognostic Imaging Biomarkers in Chemorefractory Metastatic Colorectal Cancer. *J Nucl Med.* 2018 Jun 29.
 89. **Hendlisz A**, Donckier V. The unbearable lightness of therapeutic algorithms in colorectal liver metastasis. *Curr Opin Oncol.* 2018 Jul;30(4):260-261
 90. Karfis I, Marin G, Machiels G, **Hendlisz A**, Flamen P. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event. *Clin Nucl Med.* 2018 Jul;43(7):e232-e233.
 91. Polastro L, El Hachem G, **Hendlisz A**. Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer. *Curr Opin Oncol.* 2018 Jul;30(4):269-275
 92. Massaut E, Bohlok A, Lucidi V, **Hendlisz A**, Klastersky JA, Donckier V. The concept of oligometastases in colorectal cancer: from the clinical evidences to new therapeutic strategies. *Curr Opin Oncol.* 2018 Jul;30(4):262-26
 93. Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, **Hendlisz A**. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. *Oncotarget.* 2018 Apr 3;9(25):17756-17769.
 94. Lonz C, **Hendlisz A**, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. Celyad's novel CAR T-cell therapy for solid malignancies. *Curr Res Transl Med.* 2018 May;66(2):53-56.
 95. Lemaire M, Lucidi V, Bouazza F, Katsanos G, Vanderlinden B, Levillain H, Delatte P, Garcia CA, Vouche M, Galdon MG, Demetter P, Deleporte A, **Hendlisz A**, Flamen P, Donckier V. Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study. *HPB (Oxford).* 2018 Jul;20(7):641-648.
 96. Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, **Hendlisz A**. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. *BMC Cancer.* 2019 Feb 12;19(1):134.
 97. Caparica R, Lengel   A, Bekolo W, **Hendlisz A**. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. *Autops Case Rep.* 2019 Jun 24; 9
 98. Springuel L, Lonz C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, Prenen H, **Hendlisz A**, Shaza L, Carrasco J, Canon JL, Opyrchal M, Odunsi K, Rottey S, Gilham DE, Flament A, Lehmann FF. Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. *BioDrugs.* 2019 Jul 30
 99. Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, **Hendlisz**

- A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. *Eur J Nucl Med Mol Imaging*. 2019 Oct;46(11):2270-2279.
100. Liberale G, Ameye L, [Hendlisz A](#). PRODIGE 7 should be interpreted with caution. *Acta Chir Belg*. 2019 Aug;119(4):263-266.
 101. Sclafani F, [Hendlisz A](#). Adjuvant chemotherapy for rectal cancer: playing the devil's advocate. *Curr Opin Oncol*. 2019 Jul;31(4):336-338
 102. Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, [Hendlisz A](#). CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial. . *BMC Cancer*. 2019 Apr 3;19(1):304.
 103. Delhay C, [Hendlisz A](#), Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. *Curr Opin Oncol*. 2019 Jul;31(4):339-345.
 104. Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, [Hendlisz A](#), Flamen P. Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer. *J Nucl Med*. 2019 Oct;60(10):1366-1372.
 105. Koopmansch C, Maris C, Demetter P, Van de Stadt J, [Hendlisz A](#), D'Haene N, Noël JC. Differentiated-Type Intraepithelial Neoplasia-Like Lesion Associated with Squamous Cell Carcinoma of the Anus: A Case Report with Molecular Profile Case Rep Pathol. 2019 Jan 27;2019:2301640.
 106. Duran Derijckere I, Levillain H, Bohlok A, Mathey C, Nezri J, Muteganya R, Trotta N, Lucidi V, Bouazza F, Germanova D, Van Simaey G, Goldman S, [Hendlisz A](#), Flamen P, Donckier V. The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastases. *J Surg Oncol*. 2019 Nov 12.
 107. Bregni G, Akin Telli T, Camera S, Baratelli C, Shaza L, Deleporte A, Moretti L, Bali MA, Liberale G, [Hendlisz A](#), Sclafani F. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. *Cancer Treat Rev*. 2020 Jan;82:101930.
 108. Bregni G, Akin Telli T, Camera S, Deleporte A, Moretti L, Bali AM, Liberale G, Holbrechts S, [Hendlisz A](#), Sclafani F. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. *Cancer Treat Rev*. 2020 Feb;83:101948.
 109. Akin Telli T, Bregni G, Camera S, Deleporte A, [Hendlisz A](#), Sclafani F. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. *Cancer Lett*. 2020 Jan 28;469:142-150.
 110. Camera S, Akin Telli T, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, [Hendlisz A](#). Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and LiquidBiopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. *Cancers (Basel)* 2020 Oct; 12(10): 2752.
 111. Anciaux M, Demetter P, De Wind R, Gomez Galdon M, Vande Velde S, Lens G, Craciun L, Deleruelle A, Larsimont D, Lenaerts T, Sclafani F, Deleporte A, Donckier V, [Hendlisz A](#), Vandeputte C. Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer. *BMJ Open Gastroenterol*. 2020; 7(1): e000431.
 112. Bohlok A, Lucidi V, Bouazza F, Daher A, Germanova D, Van Laethem JL, [Hendlisz A](#), Donckier V. The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases. *World J Surg Oncol*. 2020; 18: 106.
 113. Herchuelz M, Marin G, Duran Derijckere I, Vouche M, Delatte P, Donckier V, Liberale G, [Hendlisz A](#), Artigas C, Bourgeois P, Flamen P. Personalized selective internal radiation therapy in liver metastasis of thyroid cancer with impaired liver function: A case report. *Radiol Case Rep*. 2020 May; 15(5): 548–551.
 114. Pretta A, Trevisi E, Bregni G, Deleporte A, [Hendlisz A](#), Sclafani F. Treatment compliance in early-stage anal cancer. *Ann Oncol* 2020;10:1282-1284
 115. Sclafani F, [Hendlisz A](#). Editorial : Adjuvant chemotherapy for gastrointestinal cancers : we can do much better. *Curr Opin Oncol* 2020;32:344-346

116. Bouchart C, Navez J, Closset J, [Hendlisz A](#), Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes : toward a new standard ? *Ther Adv Med Oncol*. 2020 Jul 7;12:1758835920936093
117. Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, [Hendlisz A](#), de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canella R, Saragiotto D, Sabbaga J, Mak M. Malignant bowel obstruction : effectiveness and safety of systemic chemotherapy. *BMJ Support Palliat Care*. 2020 Dec 17;bmjspcare-2020-002656
118. Anciaux M, Van Gossum A, Wenglinski C, Ameye L, Guiot T, Flamen P, Demetter P, Deleporte A, Sclafani F, Donckier V, [Hendlisz A](#), Vandeputte C. Fat density is a novel prognostic marker in patients with esophagealcancer. *Clin Nutr ESPEN*. 2020 Oct;39:124-130.
119. Caparica R, Bruzzzone M, Hachem GE, Ceppi M, Lambertini M, Glasberg J, de Azambuja E, Van Laethem JL, [Hendlisz A](#). Adjuvant chemotherapy in biliary tract cancer patients : a systemic review and meta-analysis of randomized controlled trials. *Crit Rev Oncol Hematol*. 2020 May;149:102940
120. Bohlok A, Vermeulen P, Leduc S, Latacz E, Bozenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart M, [Hendlisz A](#), Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V. Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. *NPJ Breast Cancer*. 2020 Dec 18;6(1):64.
121. Camera S Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Scalfani F, [Hendlisz A](#). MOMENTUM : A phase I trial investigating 2 schedules of capecitabine with Aflibercept in patients with gastrointestinal and breast cancer. *Clin Colorectal Cancer*. 2020 Dec;19(4):311-318
122. Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, De Angelis C, [Hendlisz A](#), Awada A, Piccart M, de Azambuja. Computed tomography-based analyses of Baseline body composition parameters and changes in breast cancer patients under treatment with CDK4/6 inhibitors. *Breast Cancer Res Treat*. 2020 May;181(1):199-209
123. Asmar AE, Bendavides M, Moreau M, [Hendlisz A](#), Deleporte A, Khalife M, Donckier V, Liberale G. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. *World J Surg Oncol*. 2020 Nov 26;18(1):311
124. Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, Taraji-Shiltz L, Guix CA, Shaza L, Elbachiri M, Mans L, Machiels G, [Hendlisz A](#), Flamen P. Prognostic value of a three-scale grading system based on combining molecular imaging with ⁶⁸-Ga-DOTATATE and ¹⁸F-FDG-PET/CT in patients with metastatic Gastroentero-pancreatic neuroendocrine neoplasias. *Oncotarget*. 2020 Feb 11;11(6):589-599
125. Craciun L, de Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, Bouazza F, Vouche M, Tancredi I, Verset G, Garaud S, Naveaux C, Galdon MG, Gallo KW, [Hendlisz A](#), Derijckere ID, Flamen P, Larsimont D, Donckier V. Retrospective analysis of the immunogenic effect of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. *BMC Cancer*. 2020 Feb 19;20(1):135.
126. Bregni G Sticca T, Camea S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias L, Leduc S, Senti C, Deleporte A, Vandeputte C, saad ED, Kerger J, Piccart-Gebhart M; Awada A, Demetter P, Larsimont D, [Hendlisz A](#), Aftimos P, Sclafani F. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers as a tertiary center with a multi-gene, tumor-agnostic, next generation sequencing panel. *Acta Oncol*. 2020 Dec;59(12):1438-1446.
127. Cuyle PJ, Geboes K, Carton S, Casneuf V, Decaestecker J, De Man M, Demolin G, Deroose CM, De Vleeschouwer C, Flamen P, [Hendlisz A](#), Hoorens A, Janssens J, Karfis I, Lybaert W, Machiels G, Monsaert E, Sinapi I, Van Cutsem E, Vandamme T, Borbath I, Verslype C. Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified Delphi method. *Acta*

Gastroenterol Belg. 2020 Oct-Dec;83(4):643-653.

128. Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, **Hendlisz A**, de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canellas R, Saragiotto D, Sabbaga J, Mak M. Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy. *BMJ Support Palliat Care.* 2020 Dec 17: bmjspcare-2020-002656.
129. Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, D'Hondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, **Hendlisz A**, Sclafani F. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. *Acta Oncol.* 2021 Apr;60(4):549-553
130. Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaerden ET, **Hendlisz A**, Van den Eynde M, Donckier V, Kartheuser A, Liberale G. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. *Eur J Surg Oncol.* 2021 Jul;47(7):1661-1667.
131. Bohlok A, Duran Derijckere I, Azema H, Lucidi V, Vankerckhove S, **Hendlisz A**, Van Laethem JL, Vierasu I, Goldman S, Flamen P, Larsimont D, Demetter P, Dirix L, Vermeulen P, Donckier V. Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases. *J Surg Oncol.* 2021 May;123(8):1773-1783.
132. Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali AM, Moretti L, Troiani T, Ciardiello F, **Hendlisz A**, Sclafani F. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. *Cancer Treat Rev.* 2021 May;96:102177. doi: 10.1016/j.ctrv.2021.102177.
133. Giunta EF, Bregni G, **Hendlisz A**, Sclafani F. Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials. *Curr Opin Oncol.* 2021 Jul 1;33(4):372-377.
134. **Hendlisz A**, Sclafani F. Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last? *Curr Opin Oncol.* 2021 Jul 1;33(4):351-352
135. Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemin B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, **Hendlisz A**. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. *Cancer Med.* 2021 Jul;10(13):4366-4374. doi: 10.1002/cam4.3976. Epub 2021 May 31.
136. Ledouble V, Sclafani F, **Hendlisz A**, Gomez Galdon M, Liberale G. Buschke-Löwenstein tumor in a human immunodeficiency virus-positive patient: a case report and short literature review. *Acta Gastroenterol Belg.* 2021 Apr-Jun;84(2):343-345.
137. Monteiro AR, Conde RS, Basto R, Sclafani F, Deleporte A, **Hendlisz A**, Dal Lago L. Targeted agents in older patients with gastrointestinal cancers - An overview. *J Geriatr Oncol.* 2021 Nov;12(8):1240-1252. doi: 10.1016/j.jgo.2021.06.013. Epub 2021 Jul 2.
138. Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, **Hendlisz A**, Flamen P. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. *J Nucl Med.* 2021 Jul 29: jnumed.120.245357
139. Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, **Hendlisz A**, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. *Clin Colorectal Cancer.* 2021 Jul 24:S1533-
140. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, **Hendlisz A**, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledezine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. *J Clin Oncol.* 2021 Oct 12: JCO2101015.

141. Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, [Hendlisz A](#), Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. *Ther Adv Med Oncol*. 2021 Oct 19;13:
142. Saude Conde R, Bregni G, Saad E, [Hendlisz A](#), Sclafani F. JCOG0603: Are We Really Sure This Was a Negative Trial? *Clin Oncol*. 2022 Mar 1;40(7):803-805.
143. Ross P.J. Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeus S, [Hendlisz A](#), Ajithkumar T, Wuji C, Wilson CE, Turner D, James DC, Young E, Harris MT. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. *ESMO Open*. 2022 Feb; 7(1): 100356.
144. Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, [Hendlisz A](#), Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. *Cancer Treat Rev*. 2022 Aug 27;110:102460.
145. Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, [Hendlisz A](#), Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V. Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases. *Eur J Surg Oncol*. 2022 Aug 20;S0748-7983(22)00595-9
146. Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, D'Hondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, [Hendlisz A](#), Sclafani F. e Circulating DNA in the neoadjuvant setting of early stage colon cancer. *Acta Oncol*. 2022 Oct;61(10):1223-1229.
147. Sclafani F, [Hendlisz A](#). Circulating DNA in the neoadjuvant setting of early stage colon cancer. *Acta Oncol*. 2022 Jul 22:1-7. Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers? *Curr Opin Oncol*. 2022 Jul 1;34(4):379-381.
148. André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, [Hendlisz A](#), Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. *Ann Oncol*. 2022 Jun 25: S0923-7534(22)01737-9.
149. Saude-Conde R, Rasschaert G, Bregni G, [Hendlisz A](#), Sclafani F Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. *Curr Opin Oncol*. 2022 Jul 1;34(4):382-388
150. Saude Conde R, Bregni G, Saad E, [Hendlisz A](#), Sclafani F. JCOG0603: Are We Really Sure This Was a Negative Trial? *J Clin Oncol*. 2022 Mar 1;40(7):803-805
151. Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, [Hendlisz A](#). Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. *Cells*. 2022 Nov 18;11(22):3663
152. El Asmar A, Demetter P, Fares F, Sclafani F, [Hendlisz A](#), Donckier V, Vermeulen P, Liberale G. The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study. *Ann Surg Oncol*. 2023 Jun;30(6):3320-3328.
153. Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, [Hendlisz A](#), Di Maio M, Sclafani F - Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review - *J Natl Cancer Inst* - 2023 May 8;115(5):505-513.
154. Saude-Conde R, Nguyen D, [Hendlisz A](#) - Immunotherapies in non-metastatic gastrointestinal cancers - *Curr Opin Oncol* - . 2023 Jul 1;35(4):334-346.
155. Audisio A, Fazio R, [Hendlisz A](#), Sclafani F - Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back? *Curr Opin Oncol* - . 2023 Jul 1;35(4):315-317

156. Bohlok A, Richard F, Lucidi V, El Asmar A, Demetter P, Craciun L, Larsimont D, [Hendlisz A](#), Van Laethem JL, Dirix L, Desmedt Ch, Vermeulen P, Donckier V - Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers - *Front Oncol* - 2023 Oct 27;13:1260880.
157. Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels Ch, Vanderlinden B, Paesmans M, Ameye L, Critchi, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, [Hendlisz A](#), Flamen P, Karfis I - Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study - *J Nucl Med* - 2024 Feb 1;65(2):236-244
158. Audisio A, Fazio R, Daprà V, Assaf I, [Hendlisz A](#), Sclafani F - Neoadjuvant chemotherapy for early-stage colon cancer - *Cancer Treat Rev* - 2024 Feb;123:102676.
159. Assaf I, Fimereli D, Anthoine G, Fazio R, Daprà V, Audisio A, Bardiaux A, Akin Telli T, Vanhooren M, Saude-Conde R, Bregni G, [Hendlisz A](#), Sclafani F - Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer - *Cancers (Basel)*. 2023 Dec 13;15(24):5823.
160. Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, [Hendlisz A](#), Flamen P, Karfis I. - Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. *J Nucl Med* 2024 Feb 1;65(2):236-244. doi:10.2967.
161. Mokhtari A, Casale R, Salahuddin Z, Paquier Z, Guiot T, Woodruff HC, Lambin P, Van Laethem JL, [Hendlisz A](#), Bali MA. Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. *Diagnostics (Basel)* 2024 Mar 28;14(7):712. doi: 10.3390.
162. Hanssens C, Mouna O, Meyers M, [Hendlisz A](#). State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies. *Curr Opin Oncol* 2024 Jul 1;36(4):320-325. doi: 10.1097/CCO.0000000000001047. Epub 2024 May 7.
163. Fazio R, Audisio A, Daprà V, Conti C, Benhima N, Abbassi FZ, Assaf I, [Hendlisz A](#), Sclafani F. Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers. *Cancer Treat Rev*. 2024 Jul;128:102752. doi: 10.1016/j.ctrv.2024.102752. Epub 2024 May 12.
164. Sclafani F, Conti C, Gallio C, [Hendlisz A](#). Beyond 'the good, the bad and the ugly': let us put rectal cancer patients at the centre of the decision making. *Curr Opin Oncol*. 2024 Jul 1;36(4):305-307. doi: 10.1097/CCO.0000000000001044. Epub 2024 Jun 6.
165. Mileva M, Van Bogaert C, Marin G, Danieli R, Artigas C, Levillain H, Ameye L, Taraji-Schiltz L, Stathopoulos K, Wimana Z, [Hendlisz A](#), Flamen P, Karfis I. - 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Data From the Prospective Phase 2 LUMEN Study. *Clin Nucl Med*. 2024 Sep 1;49(9):847-853. doi: 10.1097/RLU.0000000000005330. Epub 2024 Jun 19. PMID: 38914016.
166. Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi FZ, Assaf I, Conti C, Gallio C, Benhima N, Bregni G, Gkolfakis P, Spagnolo V, Anthoine G, Liberale G, Moretti L, Martinive P, [Hendlisz A](#), Demetter P, Sclafani F. - PD-L1 Expression in Paired Samples of Rectal Cancer. *Cancers (Basel)*. 2024 Jul 21;16(14):2606. doi: 10.3390/cancers16142606. PMID: 39061244.
167. Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, Buyse M, Chibaudel B, Coart E, Diaz M, Evrard C, Geboes K, Ghiringhelli F, Puleo F, Raimbourg J, Vandamme T, Van den Eynde M, [Hendlisz A](#), Sclafani F. Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients. *Clin Colorectal Cancer*. 2024 Sep 3:S1533-0028(24)00081-1. doi: 10.1016/j.clcc.2024.08.004. Online ahead of print. PMID: 39341700
168. Meyers M, Awada A, Karfis I, t'Kint de Roodenbeke D, Couvert H, Hanssens C, [Hendlisz A](#), Driessens N. Ectopic ACTH-Dependent Cushing's Syndrome Emerging at a Late Stage of a Mixed Histology.

Neuroendocrine Neoplasm: A Case Report. *Case Rep Oncol*. 2024 Oct 14;17(1):1146-1156. doi: 10.1159/000540707. eCollection 2024 Jan-Dec. PMID: 39474561;

169. Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, **Hendlisz A**, Levillain H, Reynaert N, Flamen P, Karfis I. Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. *EJNMMI Res*. 2024 Nov 18;14(1):110. doi: 10.1186/s13550-024-01163-w. PMID: 39557730

National peer reviewed

1. Englert Y, Delvigne A, Vekemans M, Lejeune B, **Hendlisz A**, De Maertelaer G, Leroy F. Should one use fresh or frozen sperm in in-vitro fertilization with donors? *Acta Urol Belg*, 1989; 57(1):83-91.
2. Dequanter D, Lothaire Ph, **Hendlisz A**, Eisendrath P, Desmarez B, Wijns C, Andry G. Gastrostomies percutanées en carcinologie cervico-faciale : expérience de l'Institut Bordet. *Rev Laryngol Otol Rhinol* 2002; 123,1:23-26.
3. Delaunoit Th, **Hendlisz A**, Neczyporenko F, Bleiberg H. Oral therapies in colorectal cancer: a step forward? *Acta Gastroenterol Belg*. 2004 Oct-Dec; 67(4):331-3.
4. **Hendlisz A**, Personeni N, Delaunoit Th, Debroux S, Flamen P. Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes. *Acta Gastro-enterologica* 2006 Jan-Mar; 69(1):55-8.
5. Gallez J, **Hendlisz A**, Legendre H, Sirtaine N, Debroux S, Awada A. Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia] *Acta Clin Belg*. 2007 Nov-Dec;62(6):433-7.
6. **Hendlisz A**, Flamen P, Van den Eynde M, Borbath I, Demetter P, Demolin G, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem Ph, Van Laethem JL, Verslype C, Delaunoit T. Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. *Acta Gastro-enterolo Belg* 2009 Jan-Mar;72(1):44-8.
7. Verset G, Borbath I, Delaunoit T, Demetter P, Demolin G, **Hendlisz A**, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem P, Verslype C, Van Laethem JL. The potential role of targeted therapies in the management of neuroendocrine tumours. *Acta Gastroenterol Belg*. 2009 Jan-Mar; 72(1):59-62.
8. Delaunoit T, Van den Eynde M, Borbath I, Demetter P, Demolin G, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, **Hendlisz A**. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story? *Acta Gastroenterol Belg*. 2009 Jan-Mar; 72(1):49-53.
9. Verslype C, Carton S, Borbath I, Delaunoit T, Demetter P, Demolin G, **Hendlisz A**, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Hootegem P, Van Laethem JL, Van Cutsem E. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. *Acta Gastroenterol Belg*. 2009 Jan-Mar; 72(1):54-8.
10. Roeyen G, Chapelle T, Borbath I, Delaunoit T, Demetter P, Demolin G, **Hendlisz A**, Pattyn P, Pauwels S, Peeters M, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Ysebaert D. The role of surgery and transplantation in neuroendocrine tumours. *Acta Gastroenterol Belg*. 2009 Jan-Mar; 72(1):39-43. Review.
11. Dero I, De Pauw M, Borbath I, Delaunoit T, Demetter P, Demolin G, **Hendlisz A**, Pattyn P, Pauwels S, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Peeters M. Carcinoid heart disease— a hidden complication of neuroendocrine tumours. *Acta Gastroenterol Belg*. 2009 Jan-Mar; 72(1):34-8. Review.
12. Vos B, Gallez J, Debroux S, Roland S, Verhest A, Van Houtte P, Awada A., **Hendlisz A**. Concomitant chemo-radiotherapy is a standard therapy in limited-stage small-cell esophageal cancer: A summary of 3

- clinical cases and review of the literature. *Acta Gastroenterol Belg.* 2008 Jul-Sep;71(3):325-9.
13. Van den Eynde M, Lhommel R, Goffette P, Peeters M, Flamen P, **Hendlisz A**, Radioembolisation (Yttrium-90microspheres) for liver malignancies, *Belgian Journal of Medical Oncology*, 2011;5:186-92
 14. Shaza L, Charette N, **Hendlisz A**. Colorectal cancer: ten years of illusion of progress but advances are on the horizon. *Rev Med Brux.* 2015 Sep;36(4):263-6.

National and international non peer-reviewed

1. Bleiberg H, **Hendlisz A**. Surveillance postopératoire des cancers colorectaux. *La Revue du Praticien*, 1996; 46 (5): 529-531.
2. Bleiberg H, Gerard B, **Hendlisz A**, Jagodzinski R. Traitement non-chirurgical du cancer du pancréas. *Journal de chirurgie*, 1997; Sep 134 (4): 169-173.
3. **Hendlisz A**. Le cancer colorectal: l'avènement des stratégies combinées. *Tempo Médical* 2002; 231:35-37.

Chapters published in books:

1. Bleiberg H, Di Leo A, Buecher B, **Hendlisz A**. Guide pratique de la Cancérologie. Association Belge contre le Cancer 1999.
2. Mancini I, **Hendlisz A**, Body J.J. Gastrointestinal bleeding in advanced cancer patients in Gastrointestinal symptoms in advanced cancer patients. 2002 July; Chap. 14 pp 262-277.

Abstracts:

1. Bleiberg H, **Hendlisz A**, Gérard B. Treatment of advanced colorectal cancer. Second international conference on oncology Köln, Germany, 9-12 January 1995.
2. Gerard B, Bleiberg H, Michel J, Finet C, Recloux P, Diana D, Dufrane JP, Van Daele D, **Hendlisz A**, Confente C, Malarne M, Michaux D, Brienza S. Oxaliplatin combined to 5-FU and folinic acid (5FU/FA) as second-or third-line treatment in patients with advanced colorectal cancer (CRC). *Proc ASCO* 1997; 16.
3. H. Brienza S, Gerard B, Di Leo A, **Hendlisz A**, Van Daele D, Cornez N, Geurs F, Duriau D, Bertaux B, Oxaliplatin combined with a high dose 24-hour continuous 5FU infusion and folinic acid-based regimen in patients (pts) with advanced colorectal cancer (CRC). *Proc. ASCO* 1999; 18:241a (abstr 925).
4. Cornez N, Awada A, Bleiberg H, Bourgeois P, McCabe S, **Hendlisz A**, Van Daele D, De Leemput E, Bolk, Palmer M, Piccart M. A clinical pharmacodynamic and pharmacokinetic phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein given alone and in combination with Taxol in patients with solid tumors. 10th International Congress on Anti-Cancer Treatment, Paris, 31 January -3 February 2000 (oral presentation).
5. **Hendlisz A**, Di Leo A, Awada A, Castella M.L, Baize N, Caroli-Bosc FX, Van Daele D, Gillard P, Piccart M, Bleiberg H. A phase I/II study of gemcitabine (G), Cisplatin (P) and 5-fluorouracil/Folinic Acid (FU/FOL) administered as an out-patient regimen. *Proc ASCO* 2001; 20:2096.
6. Awada A, Burris H, de Valeriola D, **Hendlisz A**, Huart A, Gil T, Jones S, Martin C, Crabeels D, Litwin V, Damle B, Moerman C, Piccart M. Phase I clinical and pharmacology study of the novel epothilone BMS-247550 given weekly in patients with advanced solid tumors. Abstract presented at AACR/NCI/EORTC, Miami, 29 October - 2 November 2001. *Clin Cancer Res*, vol 7:3810s.
7. Awada A, **Hendlisz A**, Gil T, Bleiberg H, Bartholomeus S, de Valeriola D, Dewitte M, Coppieters S, Moeller JG, De Becker D, Meert AP, Piccart M. A clinical pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers. EORTC/NCI/AACR, Miami, 29 October – 2 November 2001. *Clin Cancer Res*, vol 7:3768s.
8. Bleiberg H, Huet F, Staquet, Grivergnée A, Autier P, Schrauwen AM, **Hendlisz A**, Wyns C, Panzer JM,

- Caucheteur B, Van Daele D. Screening of colorectal cancer (CRC) using sigmoidoscopy (Sig): a feasibility study on an unselected patient population. Proc. ASCO 2002; 21:175a (abst. 698).
9. Burris HA, Awada A, Jones S, Calvaert S, Crabeels D, Whitaker L, Voi M, Lebwohl D, Mac Cabe S, **Hendlisz A**, Piccart M, Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc. ASCO 2002; 21; 104a (abst. 412).
 10. Awada A, **Hendlisz A**, T. Gil, R. Muñoz, S. Bartholomeus, D. de Valeriola, J. Van der Auwera, S. Coppieters, J.G. Moeller, M. Piccart. Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumor agent. EORTC/NCI/AACR, Frankfurt, 19-22 November 2002. Abstr
 11. Nevens F, Van Vlierberghe H, D'heygere F, Delwaide J, Adler M, Henrion J, Henry JP, **Hendlisz A**, Michielsens P, Bastens B, Brenard R, Van Der Meeren O. Peginterferon alfa-2A (Pegasys) plus ribavirin (Copegus) provides similar response rate in relapsers than in naïve patients : results from the Belgian randomised trial for randomised trial for naïve and relapsers (Bernar). AASLD Meeting, Boston, 2004 . Abstr
 12. Awada A, **Hendlisz A**, Gil T, Schwartz B, Bartholomeus S, Delabaye I, de Valeriola D, Brendel E, Christensen O, Delaunoit T, Piccart M. A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in a combination with Taxotere in patients with advanced, solid tumors. EORTC/NCI/AACR – Geneva – 28 September-1 October 2004. Poster
 13. Peeters M., Van Cutsem E, Siena S, Humblet Y, **Hendlisz A**, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G. the Panitumumab Study Team (Amgen Inc). A phase 3 multicenter, randomised controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). EORTC/NCI/AACR – Praha – 7-10 November 2006. Abstr
 14. Van Cutsem E, Peeters E, Siena S, Humblet Y, **Hendlisz A**, Neyns NB, Canon JL, Van Laethem JL, Maurel J, Richardson G and the Panitumumab Study Team. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer (96/100 char). World GI, Barcelona, 28 June-1 July 2006. Abstr
 15. **Hendlisz A**, Van Cutsem E, Peeters M, Siena S, Humblet Y, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson , and the Panitumumab study team. Treatment Effect of Panitumumab by Skin Toxicity Severity: Results From a Phase 3 Randomized Controlled Trial. Poster 983PD – ESMO, Istanbul, 29 September – 3 October. *Ann of Oncol* 17 2006 (Suppl 9).
 16. Van Cutsem E, Peeters M, Siena S, Humblet Y, **Hendlisz A**, Neyns B, Canon JL, Van Laethem JL, Wolf M, Amado R. A phase 3 randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Abstract ASCO GI, Chicago, 1-5 June, 2007 – Abstr: 349.
 17. Flamen P, Huberty V, Garcia C, Vanderlinden B, Muylle K, Legendre H, Paesmans M, Van den Eynde M, **Hendlisz A**. FDG PET predicts prognosis of patients with resectable metastatic colorectal cancer (CRC) treated with preoperative chemotherapy. Proc ASCO 2007; *J Clin Oncol* 25(18S) 2007 (June 20 Suppl, abstr: 14540).
 18. **Hendlisz A**, Van Cutsem E, Peeters M, Humblet Y, Neyns B, Sobrero A, Devercelli M, Wolf R, Amado G, Siena S. Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts). Proc. ASCO 2007; *J Clin Oncol* 25(18S) 2007 (June 20 Suppl, abstr: 6560).
 19. Humblet Y. Van Cutsem E., Peeters M, Siena S, **Hendlisz A**, Neyns B, Devercelli G, Wolf M, Woolley M, Amado R. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitumumab (Pmab). Proc ASCO 2007; *J Clin Oncol* 25(18S) 2007 (June 20 Suppl, abstr 4038)
 20. Tabernero J, Sastre Valera J, Delaunoit T, Cervantes A, **Hendlisz A**, Youssoufian E, Rowinsky K, Wang G. A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human (IgGn anti-epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and

- oxaliplatin(mFOL-FOX-6) as first-line therapy. Proc ASCO 2008; *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 4066).
21. Covas A, Amininejad L, Lucidi V, Liberale G, **Hendlisz A**, Demetter P, Nagy N, Goldman S, Donckier V, Van Laethem JL. Evaluation of the correlation of complete pathologic response induced by neoadjuvant chemotherapy for colorectal liver metastases. Proc ASCO 2008; *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 4070).
 22. Demols A, Mahin C, Maréchal R, Delaunoit T, Borbath I, **Hendlisz A**, Jacquy C, Mitine C, Van Laethem JL. Cetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcinoma: A phase I study. Proc ASCO 2008; *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 4629).
 23. **Hendlisz A**, Maréchal R, Durbecq V, Rouas G, Larsimont D, Kains J, Van Laethem JL. Modulation and prognostic value of epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) during chemotherapy (CT) in patients with metastatic colorectal cancer. Proc. ASCO 2008; *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 15038).
 24. Maréchal R, Nagy N, Verrellen A, Larsimont D, **Hendlisz A**, Demols A, Demetter P, Van Laethem JL. NK Cells infiltrate in primary tumor influences responses to cetuximab (CTX) in first-line therapy of metastatic colorectal cancer (mCRC). Proc. ASCO 2008; *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 22008).
 25. **Hendlisz A**, Emonts P, Covas A, Ameye L, Paesmans M, Castany Prado Maria del Rosario A, Machiels G, Vanden Eynde M, Vanderlinden B, Flamen P. Is positron emission tomography (PET) with FDG an early predictor of the RECIST morphological response to chemotherapy in metastatic colorectal cancer patients (mCRC)? Proc. ASCO 2009; *J Clin Oncol* 27:15s, 2009 (suppl; abstr 2533).
 26. Van Den Eynde M, **Hendlisz A**, Peeters M, Defreyne L, Maleux G, Vannoote J, Delatte P, Paesmans M, Van Laethem J-L, Flamen P. Prospective randomized study comparing hepatic intra-arterial injection of Yttrium90resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver- limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT). Proc. ASCO 2009; *J Clin Oncol* 27:15s, 2009 (suppl; abstr 4096).
 27. **Hendlisz A**, Voest E, Schellens J, Awada A, Witteveen P, Stuurman R, Rasch W, Hals P. Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumors. Proc ASCO 2010. *J Clin Oncol* 28, 2010 (suppl; abstr e13078).
 28. Laffranchi, De Jonge MJ, Bajetta E, **Hendlisz A**, Giuliani R, Barone C, Endlicher E, Jannuzzo MG, Spinelli R, Santoro A. Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). Proc ASCO 2010. *J Clin Oncol* 28, 2010 (suppl; abstr e13558).
 29. Ikeda T, Duelland S, **Hendlisz A**, Dajani O, Brunsvig P, Awada A, Rao J, Farrell J, Rasch W. Phase II study of CP-4126, a gemcitabine-lipid conjugate, in patients with advanced pancreatic cancer. Proc ASCO 2010. *J Clin Oncol* 28, 2010 (suppl; abstr e14674).
 30. Stuurman FE, Voest E, Awada A, Wittenveen PO, Bergeland T, Hals PA, Schellens JHM, **Hendlisz A**. Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours. EORTC-NCI-AACR, Berlin, 16-19 Nov 2010. *Eur J Cancer* 2010; vol 8, n°7: 135 (poster #426).
 31. **Hendlisz A**, Voest E, Schellens J, Awada A, Wittenveen PO, Stuurman R, Rasch W, Hals PA. Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours. Annual meeting ASCO, Chicago, 4-8 June 2010. *J Clin Oncol* 28 (15) suppl (abstract e13078).
 32. Ikeda T, Duelland S, **Hendlisz A**, Dajani O, Awada A, Rao J, Farrell J, Rasch W. Phase II study of CP-4126, a gemcitabine-lipid conjugate, in patients with advanced pancreatic cancer. Annual meeting ASCO, Chicago, 4-8 June 2010; *J Clin Oncol* 28(15s), 2010 (abstract e14674).
 33. **Hendlisz A**, Golfinopoulos V, Garcia C, Emonts P, Covas A, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. ASCO, Chicago, 3-7 Jun 2011; *J Clin Oncol* 29(15S) Part I of II: 244s, 2011(abstract 3593).
 34. **Hendlisz A**, Van Den Eynde M, Machiels G, Dero I, Geboes K, De Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraeten E, Van Laethem JL, Lybaert W, Holbrechts S, Wouters K, Peeters M. Long-

acting octreotide as secondary prevention of chemotherapy-induced diarrhea. Belgian Week of Gastroenterology, Antwerpen, 28 February – 2 March 2012 (abstract 142 – P27).

35. **Hendlisz A**, Can Pet Imaging Help Individualize the Treatment of Colorectal Cancer Patients? 37th ESMO Congress, Vienna, 28 September – 2 October 2012 (Abstract 127IN)
36. Kalinka-Warzocha E, Gallego Plazas J, Mineur L, Salek T, **Hendlisz A**, Bendall K, Vogl D.F, Passalacqua R, Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe. Gastrointestinal Cancers Symposium, San Francisco, 24-26 January 2013 (abstract 105453) [submitted]
37. Orhac F, Soussan M, Garcia C, Vanderlinden B, **Hendlisz A**, Flamen P, Buvat I, Revisiting texture analysis for tumor characterization in FDG PET: relationship between texture indices, SUV and metabolic volumes. SNMMI 2013 Annual Meeting, Vancouver, 8-12 June 2013 [submitted]
38. Kalinka-Warzocha E, Gallego Plazas J, Mineur L, Salek T, **Hendlisz A**, Bendall K, Vogl FD, Passalacqua R. Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe. ASCO, Chicago, 31 May-4 June 2013 [submitted]
39. Prenen H, Hamm A, Wenes M, Delamarre E, D'hoore A, **Hendlisz A**, Rothé F, Sarmiento R, Tejpar S, Van Cutsem E, Schmidt T, Gasparini G, Weitz J, Mazzone M, Peripheral blood monocytes as biomarkers for colorectal cancer. ASCO, Chicago, 31 May-4 June 2013 [submitted]
40. Deleporte A, **Hendlisz A**, Garcia C, Delaunoy T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, 2d coauthor Jolimont, Van Laethem JL, Rolfo Ch, Diaz M, Lhommel R, Demolin G, Moreau M, Ameye L, Paesmans M, Piccart M, Flamen P - Metabolic assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC): the SoMore trial.. ASCO GI, San Francisco, 15 – 18 January 2014 (selected for a poster)
41. **Hendlisz A**, Deleporte A, Van Laethem JL, Vergauwe Ph, Vandeneynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, Vermeij J, D'Hondt L, Laurent S, Efra A, Gomez M Buggenhout A, Paesmans M, Garcia C, Piccart M, Flamen P and the Belgian Group for Digestive Oncology (BGDO) - Preoperative (preop) chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA trial : Eudract 2009-011445-13) interim analysis. ASCO GI, San Francisco, 15 – 18 January 2014 (accepted for an oral and poster session)
42. **Hendlisz A**, Deleporte A, T. Delaunoy, M. Peeters, G. Demolin, J. Janssens, S. Holbrechts, R. Maréchal, J. Carrasco, M. Van Den Eynde, K. P. Geboes, J.C Goeminne, L. A. D'Hondt, M. Paesmans, C. Vandeputte, F. Hoerner, P. Flamen. Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC): REGARD-C study. ASCO – Chicago – May 29th – June 03rd, 2014 (accepted for a poster session)
43. Deleporte, M. van den Eynde, F. Forget, S. Holbrechts, T. Delaunoy, G. Houbiers, H. Rezaei Kalantari, S. Laurent, E. Vanderstraeten, M. De Man, P. Vergauwe⁹, M. Clausse, J. Vanderauwera, P. Pierre¹², L. D'Hondt, Ghillemin, A. Covas, M. Paesmans, L. Ameye, **A. Hendlisz** - Weekly versus biweekly combination of Docetaxel (D)-Cisplatin (C)-5FU (F) in advanced gastric cancer and esogastric junction adenocarcinoma (aGC):DoGE Study. ESMO – Madrid – September 26th – October 01st, 2014 (accepted for a poster session)
44. Levillain.H, Marin.G, Guiot.T, Wimana.Z, Vouche.M, Delatte.P, Woff.E, **Hendlisz A**, Vanderlinden B, Flamen P. Assessment of Dose-Response correlation of Selective internal radiation therapy (SIRT) for liver metastases from colorectal cancer (mCRC) ; 30th Annual Congress of the European Association of Nuclear Medicine – October 2017 – Vienna (accepted for oral presentation)
45. Woff E, Kehagias P, Vandeputte C, Kamoun T, Guiot T, Ameye L, Geboes K, Delaunoy T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Van Laethem JL, Vergauwe P, Paesmans M, Flamen P, **Hendlisz A**. Baseline Cell-free DNA (cfDNA) and Metabolic Tumor Volume (MTV) Independently Predict Outcome in Metastatic Chemorefractory Colorectal Cancer (mCRC) - ASCO, Chicago, June 2017 [accepted for a poster]
46. Brun N, **Hendlisz A**, Shaza L, Vouche M; Donckier V, Aftimos Ph, Awada A, Lonz C, Verma B, Gilham DE, Lehmann F - A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial

- administrations of a NKG2D-based CAR-T therapy NKR-2, in patients with unresectable liver metastases from colorectal cancer. AACR Annual Meeting 2018 in Chicago, Illinois (April 14 – 18, 2018)
47. Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142' - AACR Annual Meeting 2018 in Chicago, Illinois (April 14 – 18, 2018). Poster Session
 48. Kehagias P, Vandeputte C, Ameye L, El Housni H, Laes JF, Deleporte A, Geboes K, Delaunoit Th, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Gomez Galdon M, Ghanem G, Heimann P, Paesmans M, Flamen P, [Hendlisz A](#) - circulating Tumor DNA Detects Early Response to Regorafenib in Advanced Colorectal Cancer AACR, Chicago, April 2018 (accepted for a poster)
 49. Bohlok A, Tessely H, Naets E, Bouazza F, Germanova D, Van Laethem JL, [Hendlisz A](#), Lucidi V, Donckier V. Clinical factors are unable to accurately predict the benefit of surgery in patients operated for colo-rectal liver metastases. ASCO, Chicago, June 2018 (submitted)
 50. Kehagias P, Vandeputte C, Ameye L, El Housni H, Deleporte A, Geboes K, Delaunoit Th, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe Ph, Van Laethem JL, Ghanem G, Paesmans M, Flamen P, [Hendlisz A](#) - High levels of circulating-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) are independent biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib. ASCO, Chicago, June 2018 (submitted)
 51. Derijckere D, Marin G, Desy A, Gohimont N, Woff E, Artigas C, Reynaert N, Donckier V, [Hendlisz A](#), Vanderlinden B, Flamen P. Inter-observer variability assessment for hepatic function measurement based on hepatobiliary-scintigraphy" accepted as e-poster for the next EANM congress Düsseldorf – October 2018
 52. Kopetz S, André Th, Overman MJ, Zagonel V, Lonardi S, Aglietta M, Gelsomino F, McDermott R, Mark Wong KY, [Hendlisz A](#), Garcia Alfonso P, Lenz HJ, Walsh A, Moss RA, Greenawalt D, Cao ZA. Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated With Nivolumab + Ipilimumab in CheckMate-142 (submitted AMP Europe 2018 Annual Meeting, Apr 30– May 2, 2018)
 53. Vandeputte C, Kehagias P, Ameye L, Ghislain M, Cotton F, Deleporte A, Geboes K, Delaunoit Th, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Van Laethem JL, Awada A, Paesmans M, Flamen P, [Hendlisz A](#) - Does ctDNA have more clinical value than CA19-9 as an early marker of response in advanced colorectal cancer? submitted to the Belgian Association for Cancer Research Association (BACR) Annual Meeting – February 01st, 2019 – Anvers
 54. Kehagias P, Ameye L, El Housni A, Deleporte A, Geboes K, Delaunoit Th, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Gomez Galdon M, Heimann P, Paesmans M, Flamen P, [Hendlisz A](#), Vandeputte C. - Is a single driver gene mutation sufficient for monitoring early response in advanced colorectal cancer? submitted to the AACR Annual Meeting 2019 – April 2019 – Chicago
 55. Anciaux M, Ameye L, Guiot T, Flamen P, Goldman S, Demetter P, Van Gossum A, Paesmans M, Hendlisz A, Vandeputte C. - Getting under the skin : fat quality in esophageal cancer prognosis . submitted to the AACR Annual Meeting 2019 – April 2019 – Chicago
 56. Ross P, Croagh D, Aghmesheh M, Nagrial A, Nguyen N, Nikfarjam M, Wasan H, Ajithkumar T, Iwuji C, [Hendlisz A](#), Maher T, Kraszewski A, Harris M. - PanCO: An Open-Label, Single-Arm Pilot Study of Phosphorus-32 (P- 32; Oncosil™) Microparticles in Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) in Combination with FOLFIRINOX or Gemcitabine + Nab-Paclitaxel (GNP) Chemotherapies. ASCO, Chicago, June 2019 (submitted)
 57. R Caparica, A Deleporte, JL Van Laethem, P Vergauwe, M Van Den Eynde, G Deboever, J Janssens, G Demolin, S Holbrechts, M Clausse, T Degrez, J Vermeij, L D'Hondt, K Geboes, T Besse-Hammer, A Buggenhout, M Paesmans, M Piccart, P Flamen, [A Hendlisz](#) - Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer: preliminary analysis of the PePiTA study

- ASCO, Chicago, June 2019 (submitted)
- 58. E Woff, **A Hendlisz**, L Salvatore, D Genovesi, G Critchi, L Ameye, T Guiot, H Levillain, M Paesmans, P Flamen. Validation of a Prognostic Score for Overall Survival Integrating Baseline Metabolically Active Tumor Volume by 18F-FDG PET/CT and Clinical Factors for Metastatic Colorectal Cancer Patients. ASCO, Chicago, June 2019 (submitted)
- 59. Lonez C, Rottey S, Machiels JP, Van Den Eynde M, **Hendlisz A**, Shaza L, Canon JL, Carrasco J, Cerf E, Flament A, and Lehmann F. Phase 1 studies assessing the safety and clinical activity of autologous NKG2D-based CAR-T therapy in metastatic colorectal cancer. ASCO, Chicago, June 2019 (submitted)
- 60. Woff E, **Hendlisz A**, Salvatore L, Marmorino F, Falcone A, Genovesi D, Giorgetti D, Critchi G, Guiot T, Levillain H, Flamen P. Combination of 18F-FDG PET/CT- based Metabolically Active Tumor Volume and Early Metabolic Response Significantly Improves Outcome Prediction in Metastatic Colorectal Cancer: results from two prospective internal and one external cohorts. EANM 2019 – Barcelone (submitted)
- 61. Heinz-Josef Lenz, Sara Lonardi, Vittorina Zagonel, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, **Hendlisz A**, Massimo Aglietta, Pilar García-Alfonso, Bart Neyns, Andrea Spallanzani, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Ajlan Atasoy, Jean-Marie Ledeine, Michael J. Overman. Nivolumab + Low-Dose Ipilimumab as First-Line Therapy in Microsatellite Instability-High/DNA Mismatch Repair Deficient Metastatic Colorectal Cancer: Clinical Update" ASCO 2019 in Chicago, IL (poster accepted)
- 62. Silvia Camera, Tugba Akin Telli, Erwin Woff, Pashalina Kehagias, Thomas Guiot, Gabriela Critchi, Giacomo Bregni, Andrea Pretta, Leila Shaza, Frederic Hoerner, Christos Sotiriou, Caroline Vandeputte, Francesco Sclafani, Patrick Flamen, **Hendlisz A**, Amelie Deleporte. 18F-FDG PET scan and liquid biopsy as tools to assess the pace of tumor progression and to predict overall survival (OS) in refractory colorectal cancer (rCRC): the CORIOLAN trial. ASCO, Chicago, June 2019
- 63. Peter Vermeulen*, Ali Bohlok*, Sophia Leduc, François Richard, Elia Biganzoli, Lara Botzenhart, Michail Ignatiadis, Philippe Aftimos, Christos Sotiriou, Martine Piccart, **Hendlisz A**, Steven Van Laere, Luc Dirix Jean-Christophe Noël, Valerio Lucidi, Denis Larsimont, Christine Desmedt, Vincent Donckier. Association between the histopathological growth patterns (HGP) of liver metastases (LM) and survival after hepatic surgery in patients with oligometastatic breast cancer (BC) – San Antonio - SABCS 2019 (submitted)
- 64. Shaza L, **Hendlisz A**, Awada A, Van Den Eynde M, Machiels JP, Canon JL, Carrasco J, Van Cutsem E, Dekervel J, Alcantar-Orozco E, Renard F, Cerf E, Lonez C, Flament A. Results from the completed dose-escalation of a phase I trial evaluating an autologous NKG2D CAR T-cell therapy in metastatic colorectal cancer patients. 34th Annual Meeting SITC2019 - National Harbor
- 65. Heinz-Josef Lenz, Sara Lonardi, Vittorina Zagonel, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, **Hendlisz A**, Massimo Aglietta, Pilar García Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Sandzhar Abdullaev, Arteid Memaj, Michael James Overman. Subgroup analyses of patients with microsatellite instability high/mismatch repair deficient metastatic colorectal cancer treated with nivolumab plus low dose ipilimumab as first line therapy: 2-year clinical update. ASCO GI – January 2021
- 66. Eric Van Cutsem, Sebastien Anguille, **Hendlisz A**, Jeroen Dekervel, Awada Ahmad, Emilie Cerf, Ann Dhoest, Caroline Lonez, Eytan Berman, Marie-Sophie Dheur, Erik Alcantar-Orozco, David E. Gilham, Anne Flament, Frédéric F. Lehmann, Hans Prenen. AlloSHRINK: first-in-human study of the non-gene edited allogeneic CYAD-101 NKG2D CAR T-cell product in unresectable and relapsing metastatic colorectal cancer patients - futility analysis of the Simon's two-stage expansion cohort - ASCO Abstract #332417 - 2021 ASCO Annual Meeting (June 4 - June 8, 2021)
- 67. Erwin Woff, Gabriela Critchi, Thomas Guiot, Lieveke Ameye, **Hendlisz A**, Patrick Flamen. Combined ¹⁸F-FDG PET/CT-based metabolically active tumor volume and dissemination parameter improve outcome prediction in metastatic colorectal cancer – AACR Meeting – April 2021
- 68. Mariano Ponz-Sarvisé, Elena Élez, Andrés Muñoz, Marc Van den Eynde, Antonio Gaetano Rampoldi, **Hendlisz A**, Hans Prenen, Mercedes Rodríguez, María Teresa Cano, Marya Chaney, Helena Escuin, Vanesa

Pons. Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer AACR meeting – April 2021.

69. Kehagias P., Kindt N, Krayem M, Najem A, Vandeputte C, Journée F, Awada A, Ghanem G and **Hendlisz A**. Long-Exposure to Regorafenib Induces Senescence-Like Phenotype and EMT in CRC. - AACR Meeting - April 2021
70. Bregni G, Senti C, Acedo Reina E, Gkolfakis P, Moretti L, Veron A, Demetter P, Liberale G, Carrasco J, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Buyse, Deleporte A, **Hendlisz A**, Sclafani F. REGINA: a phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC). 2022 ASCO Gastrointestinal Cancers Symposium (January 20-22, 2022)

PRESENTATIONS

2009

- **Annual meeting – BGDO / BSSO - Bruxelles - 10/01/2009**

Metastatic GI cancers : Frontiers between palliation and hope for cure - Systemic therapy and response evaluation in metastatic colorectal cancer

- **Réunion du groupement des tumeurs solides - Tivoli – 19/02/2009**

Prise en charge pluridisciplinaire des métastases hépatiques –

- **Formation universitaire spécifique en chirurgie (FUS) - Année Académique 2009-2010 – Bruxelles - 20/03/2009**

Cancers de l'estomac localement avancés : Approche péri-opératoire ou post-opératoire ?

- **Journée d'enseignement organisée par les services médico-chirurgicaux d'Oncologie Digestive de l'Hôpital Erasme et de l'Institut Bordet - Domaine du Château de Seneffe – 27/03/2009**

Traitements des métastases hépatiques du cancer colorectal : Actualités et perspectives

- **PRIX** : Award from the Kanker Plan Cancer for the project: "Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer: PePITA trial (PNC_29_059)". March 20th 2009.

2010

- **Annual meeting – BGDO / BSSO – Bruxelles - 09/01/2010**

Controversies in the Multidisciplinary Management of Rectal Cancer

- **Belgian Week of Gastroenterology - Antwerp – 05/03/2010**

Prospective randomized study comparing intra-arterial injection of Yttrium-90 resin-microspheres with protracted IV 5FU continuous infusion versus IV 5FU continuous infusion alone for patients with liver-limited metastatic colorectal cancer refractory to standard chemotherapy - Alain Hendlisz, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, Jaarke Vannoote, Katrien De Keukeleire, Chris Verslype, Luc Defreyne, Eric Van Cutsem, Philippe Delatte, Thierry Delaunoy, Nicola Personeni, Marianne Paesmans, Jean-Luc Van Laethem, Patrick Flamen.

- **Satellite symposium at the European Multidisciplinary Colorectal Cancer Congress (EMCCC) – Nice – 30/03/2010**

Clinical experience with radioembolisation for patients with mCRC failing standard-of-care chemotherapy

- **Cours Intensifs de Cancérologie Digestive - FFCD – PRODIGE – BGDO – Paris – 29/04/2010**

Traitements locorégionaux des cancers colorectaux métastatiques dans le foie

- **3ème journée oncologique de Chimay - Chimay – 29/05/2010**

- *Cancer du côlon en gériatrie*

- **Société Royale Belge de Gastro-entérologie – Bruxelles - 15/10/2010**

Comment évaluer la réponse et les objectifs à nos traitements ? Le cancer colorectal

- **Fifth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice BSMO – Bruxelles - 27/11/2010**

Surrogate markers of early response and outcome in cancer therapy. The experience in colorectal cancer

2011

- **Postgraduate course in Medical oncology National Belgian Program 2010-2011 - Bruxelles - 8/01/2011**

Role of impersonalized medicine : the example of colon cancer

- **Francophone d'Oncologie Médicale – FOM 2011- Lille - 14/01/2011**

Comment évaluer l'agressivité et la réponse d'une tumeur colorectale (imagerie et biologie)?

- **BGDO Scientific Meeting - Multidisciplinary Challenges in Colorectal Cancer - Bruxelles – 15/01/2011**

Case Report : Liver metastases of colorectal cancer

- **Belgian week of gastroenterology – Satellite symposium — 17/02/2011**

Sorafenib in advanced Hepatocarcinoma : How long should we treat?

- **Symposium SSMG/Bordet – Bruxelles – IJB - 26/02/2011 (Organisation & Moderator)**

Trajectoires en Oncologie digestive : Des avancées thérapeutiques aux nouvelles philosophies de traitement - Quelle approche pour quel patient?

- **First multidisciplinary symposium for French-speaking oncologists - Diegem – 18/03/2011**

Radioembolisation Y90 dans les tumeurs hépatiques : Perspectives et prospectives

Rôle de l'oncologue médical dans la prise en charge des tumeurs digestives - Un pour tous, Tous pour un

- **ASCO 2011 - Chicago – USA – 03/06/2011 – 07/06/2011**

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy

Hendlisz A, Golfopoulos V, Garcia C, Emonts P, Covas A, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P.

- **Société Royale Belge de Gastro-entérologie - Actualité en hépat/gastro-entérologie - Bruxelles - 15/10/2011**

Comment évaluer la réponse et les objectifs à nos traitements ? le cancer colorectal

- **Symposium de cancérologie digestive – Namur – 21/10/2011**

Qu'apporte le FDG PET comme outil prédictif

- **European School of Laparoscopy – Courses 2012 – Bruxelles – 16/11/2011**

State of the Art in Oeso-Gastric cancer

- **7ème Symposium Pluridisciplinaire d'Automne en Oncologie Digestive – Namur - 21/11/2011**

Définition précoce de la réponse au traitement anticancéreux : pourquoi et comment ? Le projet PEPITA

- **Fifth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice BSMO - Bruxelles - 25/11/2011**

Why and how early response to chemotherapy in solid tumors should be documented?

PRIX

06/04/2011 - Award from Les Amis de l'Institut Bordet asbl for the project: "Correlation of metabolic progression Index and patient's Outcome assessment in advanced Colorectal cancer disease (CORIOLAN study)".

24/11/2011 - Award from Fonds Henri & Jeanne Oehm geré par la Fondation Roi Baudouin de soutien à la recherche 2011 for the project: "Correlation of metabolic progression Index and patient's Outcome assessment in advanced Colorectal cancer disease (CORIOLAN study)".

2012

- **Belgian Week of Gastroenterology – Ostende - 10/02/2012**

Medical treatment of Neuroendocrine tumors

- **Belgian Week of Gastroenterology – Ostende - 11/02/2012**

Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea –

A Hendlisz, M. Van den Eynde, G. Machiels, I. Diero, K. Geboes, M. De Man, K/ Hendrickx, T; Delaunoit, E. Monsaert,

E. Vanderstraeten, JL Van laethem, W. Lybaert, S. Holbrechts, K. Wouters, M. Peeters

- **BGDO Digestive Oncology Course - Genk – 20/04/2012**

Molecular Biology from GI Cancer: Practical Application in Daily Clinical Practice. Evaluation of tumor response in patients treated with biologicals: challenges for the future.

- **La Journée du Président – SRBGE – Bruxelles - 28/04/2012** Moderator & speaker

Les métastases hépatiques colorectales : jusqu'où peut-on aller ?

- **37TH ESMO - Vienne – 01/10/2012**

Can PET imaging help individualize the treatment of colorectal cancer patients?

- **European School of Laparoscopy – Courses 2012 – Bruxelles – 13/11/2012**

State of the Art in Oeso-Gastric cancer

- **Postgraduate course Medical Oncology, PGMO 2012-2013 – Bruxelles - 15/12/2012**

Adjuvant Treatment of colon cancer : new standards at sight?

2013

- **Belgian Week – Anvers - BGDO session - 01/03/2013**

Highlights during the last year and perspectives for the future – Upper GI Cancer

- **Congrès de Médecine Nucléaire – Ostende – 24 – 26/02/2013**

"Patient management in oncology: role of PET/CT"

- **Chinese Society of Clinical Oncology (CISCO), - EORTC-China collaboration:**

Modular Teaching courses in GI-Oncology – March 2013

Review of Gastro-Intestinal Cancer Research

Can PET help individualize the treatment of colorectal cancer patients ?

- **European Clinical Research Workshop Oncology - Barcelone – 02/07/2013**

Regorafenib Assessment in Refractory advanced colorectal cancer: RegARd study

- **17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC2013) – Amsterdam – 30/09/2013**

Radioembolization for which patients?"

- **Symposium IPSEN - Perspectives in Gastro-Oncology – Bruxelles – 16/11/2013, chairman**

- **Cours intensif national de cancérologie digestive FFCD-PRODIGE-BGDO - Lille – 21/11/2013**

Cancers de l'œsophage et de l'estomac

Traitement médical périopératoire des cancers de l'estomac et de la jonction oesogastrique

- **2nd Belgian Symposium on Liver-Directed Cancer Therapy Using 90Y Microspheres – Bruxelles – 06/12/2013**

Future perspectives with SIR-Spheres® microspheres

2014

- **ASCO GI 2014 - Gastrointestinal Cancers Symposium – San Francisco – 15 – 19/01/2014**

Preoperative (preop) chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (CC): Interim analysis of the PEPITA study.

SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).

- **XXVIth Belgian Week of Gastroenterology- La Hulpe - February 13-15, 2014**

Preop chemosensitivity testing as predictor of adjuvant benefit in stage III colon cancer (PEPITA).

SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).

- **Francophone d'Oncologie Médicale – FOM 2011- Lille - 29/03/2014**

PET/CT précoce comme élément prédictif de réponse/résistance aux agents anticancéreux -

- **Meeting ROCHE - Angiogénèse et antiangiogénèse : Les leçons de l'expérience clinique en 2014" – Nivelles – 03/04/2014**

Antiangiogénèse des cancers digestifs : une part essentielle de l'approche thérapeutique

- **Course for Maghreb- Africa - ESMO Formation à la recherche clinique en oncologie – Maroc - 18 – 20/05/2014**

Le cancer colorectal

- **ASCO 2014 - Chicago – 30/05 – 03/06/2014**

Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC): REGARD-C study.

- **Congrès 'NeuroEndocrine Tumour Masterclass on Site', Barcelone – 04 – 05/12/2014**

Radionuclide therapy: Hot or not ?

2015

- **BGDO annual meeting – Hepatocellular Cancer - Bruxelles – 10/01/2015 –moderator**

- **AMFROM - congrès national d'oncologie médicale – Marrakech – 18/03 au 23/03/2015**

Conférence : Impact sur la pratique des actualités en cancérologie digestive.

- **Réunion scientifique de la Société Belge de Médecine Nucléaire – Bruxelles – 28/03/2015**

Multimodality imaging for treatment response prediction in colorectal cancer.

- **Séminaire Novartis - Actualisation dans la prise en charge des tumeurs neuroendocrines – Grand-Bigard – 07/05/2015, moderator**

- **Réunion inter-hospitalière en oncologie digestive ULB – Braine-l'Alleud – 21/05/2015, moderator & speaker**

Chimiothérapie périopératoire ou postopératoire : Rôle de l'évaluation de la réponse au traitement

- **18th ECCO - 40th ESMO - 32nd ESTRO European Cancer Congress (ECC2013) – Vienne - 27/09/2015**

Adjuvant chemotherapy for colorectal cancer

- **CURRENT MANAGEMENT OF BREAST AND COLON CANCER - Workshop for Medical Oncologists at Institut Jules Bordet – BXL – Belgium – 23/10/2015**

Adjuvant Treatment of Stage III Colon Cancer: How to do better?

Role of Molecular Imaging as Predictor of Outcome in Advanced Colon Cancer

- **Ninth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice-BSMO – 27/11/2015**

Gastric cancer: The role of VEGFR2, MET and HER2

2016

- **2èmes Journées scientifiques du service d'oncologie médicale de FES en partenariat avec l'Institut Jules Bordet – FES – Maroc – du 18/02/2016 au 21/02/2016**

Cancer ColoRectal: Quoi de Neuf pour 2016?

Traitement des métastases hépatiques des CCR: l'excès nuit en tout

- **Réunion inter-hospitalière en Oncologie Digestive ULB – «Approche multidisciplinaire de la maladie colorectale métastatique : "Primum non nocere" ». Mons – 12 mai 2016, moderator & speaker**

La maladie oligo-résistante

- **ESTRO School - Upper GI: technical and clinical challenges for radiation oncologists – Brussels - 28 - 31 May 2016**

State of art of chemotherapy in a combined treatment perspective

Chemotherapy toxicity constraints

- **Réunion inter-hospitalière en Oncologie Digestive ULB – «Nouvelles de l'ASCO 2016 ». Nivelles – 15 septembre 2016 Moderator and Speaker**

Le cancer colorectal

- **European Association of Nuclear Medicine – EANM – October 15th, 2016 - Barcelone**

Metabolic Response Assessment in Solid Tumours - Gastrointestinal Tumors

- **Académie royale de Médecine de Belgique - October 22nd, 2016 - Bruxelles**

Traitement médical des néoplasies coliques et rectales

- **10th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice - BSMO – Novembr , 25th, 2016 - Diegem**

Multidisciplinary approach of Esophageal cancers: How to emerge from the therapeutic status quo?

- **Réunion inter-hospitalière en Oncologie Digestive ULB – December 08th, 2016 – Braine l'Alleud**

Traitement non chirurgical et non systémique des tumeurs intra-hépatiques

2017

- **BGDO annual meeting –How to use immunotherapy & locoregional treatments- Bruxelles – 14/01/2017 – Brussels Moderator & Speaker**

Locoregional treatment in liver metastasis of colorectal cancer

- **Séminaire "les Pierre et Jules" – Séminaire gastro commun Hôpital St-Pierre et Institut Jules Bordet HSP / IJB – January 30th, 2017 – Brussels**

Tumeurs neuroendocrines : passé, présent, futur

- **BSSO - Belgian Society of Surgical Oncology npa - The Effects of Neo-adjuvant Treatment on Surgical Outcome – February 18th, 2017 – Brussels Moderator and Speaker**

The effects of neo-adjuvant chemotherapy on surgical outcome.

- **Réunion inter-hospitalière en Oncologie Digestive ULB – Les tumeurs neuro-endocrines – des actus aux guidelines – April 2017 – Nivelles, Moderator**

- **Société Luxembourgeoise d'Oncologie et de la Société Luxembourgeoise de Médecine Nucléaire – (SLO – SLMN) – Cercle de Munster - la Radio embolisation Luxembourg – May 17th, 2017**

La Radio embolisation dans le traitement des cancers et métastases hépatiques, indications actuelles et perspectives de développement

- **Symposium multidisciplinaire de pathologie digestive de l'Université de Liège 2017 – Liège - September 30th, 2017**

Imagerie métabolique et DNA tumoral circulant dans l'évaluation du cancer colorectal. Présent et futur

- **"3rd Human Cancer Immunology Course for Oncologists and Scientists" Brussels – October 06th, 2017**

Current clinical data on checkpoint inhibition in solid tumors - Gastro

- **1st ESDO - BGDO MASTERCLASS - INNOVATION IN GI CANCERS – Leuven – October 07th, 2017**

Functional imaging in GI cancer

- **Séminaire de cancérologie chirurgicale - IJB – Brussels – November 06th, 2017**

Le concept des oligométastases et son application en chirurgie hépatique

2018

- **BGDO annual meeting – ADJUVANT THERAPY: TODAY & TOMORROW- Bruxelles – January 13th, 2018 - Brussels**

Adjuvant therapy : Gastric Cancer: which perioperative strategy?

- **Certificat d'Université en Soins intégrés en Oncologie ambUlatore – Erasme – Anderlecht – January 25 & 26th, 2018**

Les traitements systémiques

CMO-partie 1 cancers digestifs

- **L'actualité sur l'hépatocarcinome – Bayer SA – Diegem – 27 mars 2018 Moderator**
- **Symposium sur les Soins de Supportifs – Institut Jules Bordet – Bruxelles – 05 mai 2018**

Thérapies ciblées : quel espoir pour les cancers du tube digestif ?

- **Le 6^{ème} congrès international du Centre Mohammed VI de traitement des cancers - Casablanca - 11 et 12 mai 2018**

Actualités thérapeutiques dans la prise en charge des cancers colo-rectaux et du cancer du sein : Traitements systémiques

- **Formation infirmier Ilya Prigogine – Bruxelles – jeudi 10 octobre 2018**

Oncologie médicale - les tumeurs digestives

2019

- **BGDO annual meeting – Curative approach in oesophageal cancer and peritoneal carcinomatosis in 2019 – Diegem – 12 janvier 2019** moderator and speaker

Peritoneal carcinomatosis

- **Certificat d'Université en Soins intégré en Oncologie ambUlatore Gestion des effets secondaires des traitements – Bruxelles – 08 février 2020**

Gestion des effets secondaires des traitements

- **ESGAR - EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY - Case-based Workshop in Upper and Lower GI Tumours – Brussels September 19 – 20, 2019**

Metastatic liver disease from GI cancers – Treatment

- **Séminaire gastros communs « Pierre-Jules » - Bruxelles, - 04 novembre 2019**

Le concept adjuvant dans les cancers digestifs

- **Réunion Bayer - Actualités en oncologie digestive” – Namur – 19 novembre 2019**

Actualités dans le cancer colorectal

- **Speaker tour “Masterclass in colorectal cancer” – Dilbeek – 25 novembre 2019 Moderator**

- **Réunions inter-hospitalières en oncologie digestive ULB, - Guidelines du tube digestif - Nivelles – le 05 décembre 2019 Moderator and Speaker**

Le cancer colorectal métastatique - Palliatif

2020

- **BGDO annual meeting – Advances in pancreaticobiliary cancers– Diegem – 11 janvier 2020 Moderator**

Genetic & molecular biology in pancreaticobiliary cancers

- **Virtual meeting - ULB NET Center Conferences : Updates in Neuro-Endocrine Tumors 2020 – 25 novembre 2020 Moderator**

2021

- **Symposium virtuel – SIRTEX - Radioembolization in 2021**

How to improve outcome for patients with liver tumors and metastases?

Metastatic Colorectal Cancer (mCRC)

- **Program Highlights of ASCO GI – Brussels - 23/02/2021 Moderator**

- **Cours intensif national de cancérologie digestive FFCD-BGDO - 20 et 21/05/2021 Moderator and speaker**

Tumeurs oeso-gastriques

Nouvelles cibles thérapeutiques en cancérologie digestive

MasterClass de la SIO : Le cancer colorectal : Nouveaux traitements et soins infirmiers : Brussels - 10/09/2021

Le cancer CRC et ses traitements anti-cancéreux

- **Masterclass ULB - Tumeurs neuro-endocrines - NET Center – Brussels - 22/10/2021 Moderator and Speaker**

Multidisciplinarity in NET Management

Interactive clinical case: the case of patient X

PRRT or SIRT in Liver-Dominant Disease? Interactive clinical case

MASTER and PhD THESIS SUPERVISION

Date	Name	Title	
2008	CASTANY PRADO Maria del Rosario	"Le rôle du FDG-Pet dans l'évaluation précocede la réponse à la chimiothérapie dans le cancer colorectal métastatique".	Master Thesis Medical Oncology Promotor
2009	VAN VAERENBERGH Muriel	Etude critique du bénéfice de la chimiothérapie dans le traitement du cholangiocarcinome au stade avancé ou récidivant.	Master Thesis Medicine Co-promotor
2011	VANDER CASSYEN Virginie	La nutrition du patient cancéreux	Master Thesis Pharmacy Promotor
2013	MOHEMMANE Amal	Aspects radiopharmaceutiques de l'installation à l'Institut Bordet d'un programme de soin par radiothérapie métabolique par des peptides radiomarqués (PRRT) pour des patients atteints de tumeurs neuroendocrines généralisées.	Master Thesis Pharmacy Promotor
2014	PAYAN Bruno	Aspects pharmaceutiques d'une étude de phase II évaluant la réponse métabolique duregorafenib dans le cancer colorectal métastaté réfractaire à toute chimiothérapie.	Master Thesis Pharmacy Promotor
2016	LAPLANTINE Bartholomé	Analysis of the effect of chemotherapy on tumor-infiltrating immune cells in stage II/IIIcolon cancer	Master Thesis Medicine Promotor
2016	VAN BOGAERT Camille	The Influence of Body Composition on theOutcome of Patients with Refractory advanced Colorectal Cancer	Master Thesis Medicine Promotor
2018	GHISLAIN Maxime	Utilisation du CEA, CA 19-9 et de l'ADN circulant dans le suivi du cancer colorectalmétastatique	Master Thesis Medicine Promotor
2019	WENGLINSKI Cynthia	Impact pronostic de la composition corporelle(BMC) dans le cancer de l'œsophage localement avancé	Master Thesis Medicine Promotor
2019	PETERSBOURG Duncan	Monitoring de la mutation KRAS par biopsie liquide dans le cancer du pancréas avancé(Limonade-P study)	Master Thesis Medicine Promotor
2019	WISSAM Yacine	Are clinical, biological and imaging parametersable to assess the survival of patients with chemorefractory advanced colorectal cancer potentially candidates for inclusion in phase I trials?	Master Thesis Medical Oncology Promotor
2019	WAGNER Antoine	l'Implémentation clinique d'une plate- forme Monte Carlo pour la validation detraitements de radiothérapie stéréotaxique et par modulation d'intensité	PhD Thesis Medical Sciences Jury Chair

2019	BOHLOK Ali	Research of biomarkers to predict the benefit of surgery in patients with livermetastases	PhD Thesis Medical Sciences Co-promotor
2020	LEVILLAIN Hugo	Prediction and improvement of radioembolization outcome using personalised treatment and dosimetry	PhD Thesis Medical Sciences Président de jury
2020	KEHAGIAS Pashalina	Sensitivity and Resistance to Regorafenib Therapy in AdvancedColorectal Cancer: ctDNA Monitoring and MolecularMechanisms	PhD Thesis Biomedical & Pharmaceutical Sciences Promotor
2020	ANCIAUX Maëlle	Prognostic value of macro- andmicroenvironment parameters in esophageal cancer. Exploration of candidate biomarkers at morphological, histopathological andmolecular levels	PhD Thesis Biomedical & Pharmaceutical Sciences Co-promotor
2020	WOFF Erwin	Are clinical, biological and imaging parameters able to assess the survival of patients with chemorefractory advanced colorectal cancer potentially candidates for inclusion in phase Itrials?	PhD Thesis Medicine Co-promotor
2021	COUSSEMENT Mina	The impact of neoadjuvant therapy on PD-L1 expression in rectal cancer and its microenvironnement	Master Thesis Medicine Promotor
2023	LEDUC Sophia		PhD Thesis Medical Sciences Accompanying Comittee Chair